PMID- 17016660
OWN - NLM
STAT- MEDLINE
DCOM- 20061222
LR  - 20131121
IS  - 1019-6439 (Print)
IS  - 1019-6439 (Linking)
VI  - 29
IP  - 5
DP  - 2006 Nov
TI  - Efficient induction of specific cytotoxic T lymphocytes to tumor rejection 
      peptide using functional matured 2 day-cultured dendritic cells derived from 
      human monocytes.
PG  - 1263-8
AB  - Dendritic cells (DCs) are powerful antigen-presenting cells (APCs), that have so 
      far been applied for cancer specific immunotherapy. Recent results suggest that 
      matured DCs derived from human monocytes have a significant impact on the outcome 
      of vaccination. The conventional generation of mature DCs from human monocytes in 
      vitro has been reported to require 5 days for differentiation with granulocyte 
      macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-4 and 2 days for 
      stimulation. We herein report a new strategy for the functional maturation of 
      monocyte-derived DCs within only 2 days of in vitro culture and the induction of 
      specific cytotoxic T lymphocytes (CTLs) to tumor rejection peptide. The monocytes 
      were incubated for 1 day with GM-CSF and IL-4, followed by activation with a 
      bacterial product, OK-432 and prostaglandin E2 (PGE2) for another 1 day (rapid 
      DC). Rapid DC expressed mature DC surface markers as well as chemokine receptor 7 
      and secreted Th1-type cytokines. The DCs generated in this study mobilized Ca2+ 
      in response to CCL21/6Ckine and SDF-1, but only marginally did so to Mip-1alpha. 
      Moreover, when rapid DC were compared with mature conventional 7-day DCs, they 
      were equally potent in inducing specific CTLs in vitro. These results indicate 
      that the rapid DC is as effective as the monocyte-derived conventional DCs. The 
      rapid DC would be a potentially useful new cancer-specific immunotherapy.
FAU - Tanaka, Fumiaki
AU  - Tanaka F
AD  - Division of Molecular and Surgical Oncology, Department of Molecular and Cellular 
      Biology, Medical Institute of Bioregulation, Kyushu University, Beppu 874-0838, 
      Japan.
FAU - Yamaguchi, Hiroshi
AU  - Yamaguchi H
FAU - Haraguchi, Naotsugu
AU  - Haraguchi N
FAU - Mashino, Kohjiro
AU  - Mashino K
FAU - Ohta, Mitsuhiko
AU  - Ohta M
FAU - Inoue, Hiroshi
AU  - Inoue H
FAU - Mori, Masaki
AU  - Mori M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Greece
TA  - Int J Oncol
JT  - International journal of oncology
JID - 9306042
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (CCL21 protein, human)
RN  - 0 (CXCL12 protein, human)
RN  - 0 (Chemokine CCL21)
RN  - 0 (Chemokine CXCL12)
RN  - 0 (Chemokines, CC)
RN  - 0 (Chemokines, CXC)
RN  - 0 (Cytokines)
RN  - 0 (HLA-A Antigens)
RN  - 0 (HLA-A28 antigen)
RN  - 0 (MAGEA3 protein, human)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Peptides)
RN  - 187348-17-0 (Interleukin-12)
RN  - 39325-01-4 (Picibanil)
RN  - 82115-62-6 (Interferon-gamma)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Antigens, Neoplasm/pharmacology
MH  - Calcium/metabolism
MH  - Cell Culture Techniques/*methods
MH  - Chemokine CCL21
MH  - Chemokine CXCL12
MH  - Chemokines, CC/pharmacology
MH  - Chemokines, CXC/pharmacology
MH  - Coculture Techniques
MH  - Cytokines/metabolism
MH  - Dendritic Cells/cytology/*immunology/transplantation
MH  - Dinoprostone/pharmacology
MH  - HLA-A Antigens/pharmacology
MH  - Humans
MH  - *Immunotherapy, Adoptive
MH  - Interferon-gamma/metabolism
MH  - Interleukin-12/metabolism
MH  - Monocytes/*cytology/drug effects
MH  - Neoplasm Proteins/pharmacology
MH  - Peptides/pharmacology
MH  - Picibanil/pharmacology
MH  - T-Lymphocytes, Cytotoxic/*immunology
MH  - Th1 Cells/immunology
EDAT- 2006/10/04 09:00
MHDA- 2006/12/23 09:00
CRDT- 2006/10/04 09:00
PHST- 2006/10/04 09:00 [pubmed]
PHST- 2006/12/23 09:00 [medline]
PHST- 2006/10/04 09:00 [entrez]
PST - ppublish
SO  - Int J Oncol. 2006 Nov;29(5):1263-8.